Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.36 |
| ▸ | CCKBR | P32239 | 1/20 | 0.35 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.35 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21943867 | 0.96 | KMT2A (0.49) | KMT2APOLBL3MBTL1FOLH1CYP1A2 | |
| SCHEMBL19594663 | 0.96 | KMT2A (0.49) | KMT2APOLBL3MBTL1FOLH1CYP1A2 | |
| SCHEMBL13400091 | 0.93 | FOLH1 (0.49) | KMT2APOLBL3MBTL1FOLH1SMN1; SMN2 | |
| SCHEMBL13400056 | 0.93 | FOLH1 (0.49) | KMT2APOLBL3MBTL1FOLH1SMN1; SMN2 | |
| SCHEMBL2742777 | 0.93 | FOLH1 (0.49) | KMT2APOLBL3MBTL1FOLH1SMN1; SMN2 | |
| SCHEMBL14048625 | 0.89 | FOLH1 (0.44) | KMT2APOLBL3MBTL1FOLH1SMN1; SMN2 | |
| SCHEMBL14048647 | 0.88 | FOLH1 (0.58) | FOLH1TSHRCPB2SLC6A5 | |
| SCHEMBL13515320 | 0.85 | FOLH1 (0.42) | KMT2APOLBL3MBTL1FOLH1SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL1276507 | 0.85 | FOLH1 (0.45) | KMT2APOLBL3MBTL1FOLH1SMN1; SMN2 | |
| SCHEMBL14930704 | 0.85 | TSHR (0.56) | KMT2APOLBL3MBTL1FOLH1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200085758-A1 | CO-DELIVERY OF NUCLEIC ACIDS FOR SIMULTANEOUS SUPPRESSION AND EXPRESSION OF TARGET GENES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200085758-A1 | CO-DELIVERY OF NUCLEIC ACIDS FOR SIMULTANEOUS SUPPRESSION AND EXPRESSION OF TARGET GENES | AGO2, DCLRE1A, RNASE1 | KMT2A 3921/4885POLB 229/4885L3MBTL1 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.